Other
Change in Deferred Revenue
Year-over-year, this metric grew by 94.0%, from -$27.32M to -$1.63M. Over 3 years (FY 2022 to FY 2025), Change in Deferred Revenue shows an upward trend with a -7.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementIncome Statement
SectionOther
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
How to read this metric
An increase is generally positive, signaling strong future revenue visibility and customer commitment.
Detailed definition
Measures the net change in payments received from customers for goods or services that have not yet been delivered or ea...
Peer comparison
Highly relevant for subscription or long-cycle businesses; compared against peers with similar revenue models.
Metric ID:
anet_change_in_deferred_revenueHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$23.94M | -$8.35M | -$12.33M | $158.00K | -$12.47M | -$41.28M | -$8.85M | $21.72M | $24.47M | $17.69M | -$28.56M | -$190.94M | -$3.13M | -$12.81M | -$27.32M | -$13.08M | -$12.54M | $0.00 | -$1.63M |
| QoQ Change | — | +65.1% | -47.6% | +101.3% | <-999% | -231.2% | +78.6% | +345.4% | +12.7% | -27.7% | -261.5% | -568.5% | +98.4% | -309.3% | -113.3% | +52.1% | +4.1% | +100.0% | — |
| YoY Change | — | — | — | +100.7% | -49.2% | — | +28.2% | >999% | +296.3% | +142.9% | -222.7% | -979.3% | -112.8% | -172.4% | +4.3% | +93.2% | -300.6% | +100.0% | +94.0% |
Range-$190.94M – $24.47M
CAGR-44.9%
Avg YoY Growth+844.4%
Median YoY Growth+28.2%
Current Streak4 quarters growth
Change in Deferred Revenue at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's change in deferred revenue?
- Alnylam Pharmaceuticals (ALNY) reported change in deferred revenue of -$1.63M in Q1 2026.
- How has Alnylam Pharmaceuticals's change in deferred revenue changed year-over-year?
- Alnylam Pharmaceuticals's change in deferred revenue increased by 94.0% year-over-year, from -$27.32M to -$1.63M.
- What is the long-term trend for Alnylam Pharmaceuticals's change in deferred revenue?
- Over 3 years (2022 to 2025), Alnylam Pharmaceuticals's change in deferred revenue has grown at a -7.0% compound annual growth rate (CAGR), from -$65.91M to -$52.94M.
- What does change in deferred revenue mean?
- The change in payments received for work not yet completed.